Opendata, web and dolomites

MeningoSpeed SIGNED

A unique cost-effective and point of care (PoC) kit for the non-invasive rapid in vitro diagnosis of meningococcal disease

Total Cost €


EC-Contrib. €






 MeningoSpeed project word cloud

Explore the words cloud of the MeningoSpeed project. It provides you a very rough idea of what is the project "MeningoSpeed" about.

pcr    accumulated    company    permanent    hospital    healthcare    care    performance    diseases    vast    serogroups    meningospeed    reducing    sequelae    mainly    epidemic    rapid    children    savings    sensitivity    physicians    technological    nm    least    lack    nanoparticle    business    commercial    purchasers    deaths    six    france    projected    2022    specificity    neisseria    opportunity    infectious    treatment    despite    launch    successful    gold    accuracy    financial    33    tool    public    solution    min    pasteur    direct    fashion    capability    spin    biospeedia    secure    burden    costly    annually    market    tests    added    disease    demonstrated    15    3h    alternatives    25    competitive    ca    meningococcal    diagnostic    societal    people    abcxwy    limited    finalize    cagr    valued    2026    million    immunochromatographic    point    first    tools    lethality    off    caused    monitoring    cheaper    net    10    disruptive    plan    profitable    lt    93    latex    unmet    faster    core    acute    patients    vitro    worldwide    profit    accurate    health    vs    agglutination    gt    feasibility    source    young    md    invasive    meningitidis    diagnosis    68    45   

Project "MeningoSpeed" data sheet

The following table provides information about the project.


Organization address
city: PARIS
postcode: 75724
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2019-06-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOSPEEDIA FR (PARIS) coordinator 50˙000.00


 Project objective

Meningococcal disease (MD), caused by Neisseria meningitidis serogroups (mainly ABCXWY), annually affects 1.2 million people worldwide (mainly children and young). Due to its high lethality (8-15% treated patients), permanent sequelae and epidemic potential, MD represents a major public health problem. Despite the societal burden, there is a lack of rapid and accurate diagnostic tools for timely and early treatment that results very costly for healthcare systems (e.g. direct costs valued in € 68 m/hospital/year). In response to the unmet need, BioSpeedia (spin-off from the Institute Pasteur, France) has vast experience in infectious diseases management and is developing the first-ever gold nanoparticle-based immunochromatographic test with demonstrated diagnostic capability for the six Nm serogroups. MeningoSpeed is a non-invasive, accurate (sensitivity and specificity >93%), rapid (<15 min vs PCR: 3h) and cost-competitive in vitro diagnostic test (€45 sample, at least 25 % cheaper than latex agglutination tests and PCR alternatives) for MD diagnosis. Our one-step solution will result on added value for patients, physicians and healthcare purchasers by improving disease monitoring in an accurate and timely fashion way, reducing deaths and sequelae. MeningoSpeed will provide healthcare systems with limited resources with a reliable and cost-effective diagnostic tool, leading to significant cost-savings. MeningoSpeed´s high accuracy and performance under a faster and cheaper cost make it a disruptive solution with great potential for commercial success in the growing point-of-care market (€33 B by 2022, CAGR 10%). Thus, MeningoSpeed is projected to be a profitable business opportunity and a core source of growth for the company (ca. €33 M of accumulated net profit during 2022-2026). A next feasibility study covering the technological, commercial and financial issues will enable us to finalize our business plan and secure our steps towards the successful market launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MENINGOSPEED" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MENINGOSPEED" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

CoLumbo (2019)


Read More  

Nocturne (2019)

The eye as a window to the brain, extending lifelong brain health

Read More  

Tolka Pro (2019)

Manual Assistant (hand for upper limb disability) – a new approach designed to restore user's manual capabilities.

Read More